4-Propan-2-yl-[1,3]thiazolo[4,5-c]pyridine | 1228149-69-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 4-Propan-2-yl-[1,3]thiazolo[4,5-c]pyridine
• 英文别名: 4-propan-2-yl-[1,3]thiazolo[4,5-c]pyridine
• CAS: 1228149-69-6
• 化学式: C₉H₁₀N₂S
• 分子量: 178.258
• InChiKey: HSDIQXRBOJMBJB-UHFFFAOYSA-N

物化性质

• 沸点：
  274.7±20.0 °C(Predicted)
• 密度：
  1.191±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  54
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  [(3aS,4R,6R,6aR)-4-[(5-iodo-6-methyl-2-methylsulfanylpyrimidin-4-yl)amino]-2,2-dimethyl-4,5,6,6a-tetrahydro-3aH-cyclopenta[d][1,3]dioxol-6-yl]methanol 、 4-Propan-2-yl-[1,3]thiazolo[4,5-c]pyridine 在 copper(l) iodide 、 四(三苯基膦)钯 、 caesium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成
  参考文献：
  名称：

  Synthesis and SAR of pyridothiazole substituted pyrimidine derived HCV replication inhibitors

  摘要：

  Introduction of a nitrogen atom into the benzene ring of a previously identified HCV replication (replicase) benzothiazole inhibitor 1, resulted in the discovery of the more potent pyridothiazole analogues 3. The potency and PK properties of the compounds were attenuated by the introductions of various functionalities at the R-1, R-2 or R-3 positions of the molecule (compound 3). Inhibitors 38 and 44 displayed excellent potency, selectivity (GAPDH/MTS CC50), PK parameters in all species studied, and cross genotype activity. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.06.099
• 作为产物：
  描述：

  4-氯噻唑并[4,5-C]吡啶 、 triisopropylaluminium 在 四(三苯基膦)钯 作用下， 以 1,4-二氧六环 、 正己烷 为溶剂， 以70%的产率得到4-Propan-2-yl-[1,3]thiazolo[4,5-c]pyridine
  参考文献：
  名称：

  功能化噻唑并[4,5- c ]吡啶的新方法

  摘要：

  新型取代的噻唑[4,5- c ]吡啶已通过直接的C-H偶联反应和N-氧化物重排化学反应，由未取代的噻唑[4,5- c ]吡啶合成而得。

  DOI：

  10.1016/j.tetlet.2010.03.069

文献信息

• SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME
  申请人：BlinkBio, Inc.

  公开号：US20170202970A1

  公开（公告）日：2017-07-20

  Described herein are silicon based conjugates capable of delivering one or more payload moieties to a target cell or tissue. Contemplated conjugates may include a silicon-heteroatom core, one or more optional catalytic moieties, a targeting moiety that permits accumulation of the conjugate within a target cell or tissue, one or more payload moieties (e.g., a therapeutic agent or imaging agent), and two or more non-interfering moieties covalently bound to the silicon-heteroatom core.

  本文描述了基于硅的共轭物，能够将一个或多个有效载荷基团传递到靶细胞或组织。考虑到的共轭物可能包括一个硅-杂原子核心，一个或多个可选的催化基团，一个定位基团，允许共轭物在靶细胞或组织内积累，一个或多个有效载荷基团（例如，治疗剂或成像剂），以及与硅-杂原子核心共价结合的两个或更多个不干扰基团。
• Syntheses of 4- and 6-substituted thiazolo[4,5-c]pyridines
  作者：Yuhua Huang、Frank Bennett、Vinay Girijavallabhan、Carmen Alvarez、Tze-Ming Chan、Rebecca Osterman、Mary Senior、Cecil Kwong、Namita Bansal、F. George Njoroge、Malcolm MacCoss

  DOI：10.1016/j.tetlet.2010.03.070

  日期：2010.5

  A general synthetic approach to 4,6-substituted thiazole[4,5-c]pyridines, involving a novel one-pot thiol deprotection-cyclization key step, is described.

  描述了一种4,6-取代的噻唑[4,5- c ]吡啶的一般合成方法，涉及一个新的一锅硫醇脱保护环化关键步骤。
• CXCR4 inhibitors and uses thereof
  申请人：X4 Pharmaceuticals, Inc.

  公开号：US10759796B2

  公开（公告）日：2020-09-01

  The present invention provides compounds, compositions thereof, and methods of using the same.

  本发明提供了化合物、其组合物以及使用方法。
• QUINOLIZINONE DERIVATIVES AS PI3K INHIBITORS
  申请人：Lupin Limited

  公开号：US20170137421A1

  公开（公告）日：2017-05-18

  Disclosed are compounds of formula (I), their tautomeric forms, stereoisomers, and pharmaceutically acceptable salts thereof, wherein R 1 -R 4 , and n are as defined in the specification, pharmaceutical compositions including a compound, tautomer, stereoisomer, or salt thereof, and methods of treating or preventing diseases or disorders, for example, cancer, that are amenable to treatment or prevention by inhibiting the PI3K enzyme of a subject.
• HETEROCYCLIC INHIBITORS OF MONOCARBOXYLATE TRANSPORTERS
  申请人：THE SCRIPPS RESEARCH INSTITUTE

  公开号：US20180002343A1

  公开（公告）日：2018-01-04

  The invention provides compounds that inhibit monocarboxylate transporters, such as MCT1 and MCT4. Compounds of the invention can be used for treatment of a condition in a patient, wherein the condition is characterized by the heightened activity or by the high prevalence of MCT1 and/or MCT4, such as cancer or type II diabetes.